Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL-0817 plus cyclophosphamide vs placebo for prevention of recurrence in high-risk oral cavity squamous cell carcinoma
2016-001256-22Phase 2Terminated
- Sponsor
- Gliknik
- Start
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Oral Mucosal Carcinoma comparing GL-0817 combination arm with Placebo combination arm (2 arms). Primary endpoint: 2-year disease-free interval. Started Aug 2016; status: terminated.
02
Drugs
biropepimut-s
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2016-001256-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001256-22.